PORTLAND, Ore., July 20, 2015 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced that it will report second quarter 2015 financial results before the open of U.S. financial markets on July 31, 2015. Doug Murphy-Chutorian, M.D., chief executive officer of Semler, will host a conference call at 11 a.m. ET the same day.
The conference call may be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you would like to join the "Semler Second Quarter 2015 Financial Results Call, conference ID#: 87674841." The conference call will be archived on Semler's website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases. Semler's first patented and U.S. Food and Drug Administration cleared product, is FloChec®. FloChec® is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. Additional information about Semler can be found at www.semlerscientific.com.
SOURCE Semler Scientific, Inc.